Spotting non-relapsing progressive MS earlier

Credibility

Interest

Key Takeaway

A data-driven definition (adapted HERCULES) can spot a group of non-relapsing secondary progressive MS patients earlier and more consistently than doctor-recorded labels.

What They Found

Researchers used a set of clear, checklist-like rules (adapted from a trial called HERCULES) to find people with secondary progressive MS (SPMS) who do not have relapses. Using those rules on a large Italian registry, they identified about 7.9% of patients as non-relapsing SPMS, compared with 4.3% labeled by neurologists. The group found by the HERCULES rules tended to be older and had fewer relapses after they were classified as SPMS. Most patients in both groups showed disability getting worse without relapses (called PIRA — think of slow steady worsening like a dimmer switch turning down over time), and this steady worsening showed up sooner in the HERCULES-identified group. The algorithm was very good at avoiding false positives (it rarely labeled someone as SPMS who was not), but it missed many who clinicians had labeled SPMS, meaning it had low sensitivity.

Who Should Care and Why

People living with MS and their caregivers should care because standardized rules can find a subgroup of patients whose disability gets worse mainly without relapses — this matters for planning care and treatments that target slow progression rather than flare-ups. Neurologists and clinics that track patients in registries can use these rules to spot progression earlier and more consistently, like using the same measuring tape instead of different ones. Patients who stop having relapses but notice steady decline (for example, slowly needing more help walking or with daily tasks) may be in this group and could discuss different treatment or rehab options with their care team. Caregivers can use this information to watch for steady changes over time (for example, small daily increases in fatigue or walking difficulty) and report them to clinicians even if there are no relapses. Health systems and researchers benefit because standardized definitions help compare patients and treatments across studies, similar to everyone using the same recipe so results are comparable.

Important Considerations

The adapted HERCULES rules were tested on registry data, which may miss some details doctors see in clinic, so the algorithm can miss people who truly have SPMS (it had low sensitivity). Because the study used past records from one national registry, results might differ in other countries or clinics with different care patterns. This means patients should not change treatment on their own based on these findings — discuss any concerns with your neurologist who can consider both the checklist and your full clinical picture.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression MS Diagnostics Living with MS

Article Topics:

Data-driven algorithmDisease registryMultiple sclerosisNonrelapsing SPMSSecondary progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News